A Randomized, Double-Blind, Phase III Multi-Center Study Evaluating the Safety and Efficacy of BF-200 ALA Versus Placebo in the Treatment of Actinic Keratosis (AK) When Using PDT

Trial Profile

A Randomized, Double-Blind, Phase III Multi-Center Study Evaluating the Safety and Efficacy of BF-200 ALA Versus Placebo in the Treatment of Actinic Keratosis (AK) When Using PDT

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Aminolevulinic acid (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Feb 2016 Results from this trial will be presented at the 14th Annual South Beach Symposium, according to a Biofrontera media release.
    • 27 Jan 2011 Biofrontera has received a positive interim report of the responsible committee of the European Medicines Agency, according to a company media release.
    • 16 Dec 2010 According to a Biofrontera media release, EMEA has sent official summaries and preliminary questions of the reviewers about the approval dossier, and subject to satisfactory answers to the questions raised, the review will recommended the drug approval.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top